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http://dx.doi.org/10.1016/j.ccr.2013.04.020SUMMARYGene expression profiling has uncovered the transcription factor Sox4 with upregulated activity during TGF-
b-induced epithelial-mesenchymal transition (EMT) in normal and cancerous breast epithelial cells. Sox4 is
indispensable for EMT and cell survival in vitro and for primary tumor growth and metastasis in vivo. Among
several EMT-relevant genes, Sox4 directly regulates the expression of Ezh2, encoding the Polycomb group
histone methyltransferase that trimethylates histone 3 lysine 27 (H3K27me3) for gene repression. Ablation of
Ezh2 expression prevents EMT, whereas forced expression of Ezh2 restores EMT in Sox4-deficient cells.
Ezh2-mediated H3K27me3 marks associate with key EMT genes, representing an epigenetic EMT signature
that predicts patient survival. Our results identify Sox4 as amaster regulator of EMT by governing the expres-
sion of the epigenetic modifier Ezh2.INTRODUCTION
Epithelial-mesenchymal transition (EMT) is a cellular mechanism
known to constitute the core of normal embryonic development
(Hanahan and Weinberg, 2011; Kalluri, 2009; Kalluri and Wein-
berg, 2009; Nieto, 2010; Polyak and Weinberg, 2009; Thiery
and Sleeman, 2006). Similar, yet pathophysiological transitions
occur during the progression of epithelial tumors, endowing
cancer cells with increased motility and invasiveness to seed
metastasis and, sometimes, after metastatic dissemination to
redifferentiate into epithelial structures by mesenchymal-epithe-
lial transition (Kang and Massague´, 2004; Thiery and Morgan,
2004). Multiple oncogenic events and signaling pathways, medi-
ated, for example, by transforming growth factor b (TGF-b),
hepatocyte growth factor (HGF), Wnt and Notch signaling, orSignificance
An epithelial-mesenchymal transition (EMT) is a key process du
lial tumors tometastatic cancers. Here, we identify the transcrip
to act highly upstream in the epistatic hierarchy of EMT regulati
Ezh2. Conversely, Ezh2 is able to functionally replace Sox4
EMT-associated genes. Ezh2 thus represents one critical Sox4
interplay between transcriptional and epigenetic control durin
attractive avenue for the therapeutic intervention of malignant
768 Cancer Cell 23, 768–783, June 10, 2013 ª2013 Elsevier Inc.oncogenic Src or Ras activation, are implicated in the induction
of EMT (Hanahan and Weinberg, 2011; Kalluri, 2009; Kalluri and
Weinberg, 2009; Nieto, 2010; Polyak andWeinberg, 2009; Thiery
and Sleeman, 2006).
Sox4 is a member of the Sox (SRY-related HMG-box) family of
transcription factorswith acritical role in embryonic development
and in cell-fate determination during organogenesis of the heart
(Restivo et al., 2006; Schilham et al., 1996), pancreas (Lioubinski
et al., 2003; Wilson et al., 2005), and brain (Cheung et al., 2000;
HongandSaint-Jeannet, 2005), and inBandT lymphocyte differ-
entiation (Cheung et al., 2000; Hong and Saint-Jeannet, 2005;
Lioubinski et al., 2003; Schilham et al., 1996, 1997; van deWeter-
ing et al., 1993; Wilson et al., 2005). Sox4 gene expression is
upregulated in many cancer types, and increased Sox4 activity
contributes to cellular transformation (Liu et al., 2006; Shinring organismal development and the progression of epithe-
tion factor Sox4 as amaster regulator of EMT. Sox4 appears
on. It controls a number of EMT-relevant genes in addition to
during EMT and regulates the expression of a number of
target gene during EMT. The results exemplify an important
g EMT and suggest that the inhibition of Ezh2 could be an
tumor progression.
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et al., 2006; Pramoonjago et al., 2006), andmetastasis (Liao et al.,
2008; Tavazoie et al., 2008). For example, restoration of miR-335
expression suppresses lung and bone metastasis in human
cancer cells by interfering with the expression of Sox4 (Tavazoie
et al., 2008). Interestingly, Sox4 also directly modulates key
cellular regulators, including the genes encoding for epidermal
growth factor receptor (EGFR), tenascin-C, heat shock protein
70 (Hsp70), frizzled homolog 5 (Fzd5), Delta-like 1 (Dll1), and
Patched-1 (Ptch1), the transcriptional regulators Mll, Foxa1,
Znf281, and Nkx3-1, and components of the RNAi machinery,
including Dicer, Argonaute 1, and RNA helicase A (Scharer
et al., 2009). Finally, Sox4 regulates Wnt signaling by directly
binding to b-catenin and Tcf family members (Sinner et al.,
2007). Most recently, Sox4 has been reported to induce EMT
and to cooperate with oncogenic Ras in breast cancer progres-
sion (Zhang et al., 2012); however, its direct transcriptional target
genes during EMT have remained elusive. Here, we demonstrate
a central role of Sox4 in EMT as well as in primary tumor growth
andmetastasis by directly regulating the expression of a number
of genes with critical functions in EMT, including Ezh2.
The histonemethyltransferase Ezh2 (Enhancer of Zeste homo-
log 2) is a component of the Polycomb (PcG) repressive complex
2 (PRC2), which epigenetically regulates genes involved in cell
fate decisions. Ezh2 specifically trimethylates nucleosomal his-
tone H3 at lysine 27 (H3K27me3), an epigenetic modification
associated with gene silencing (Sparmann and van Lohuizen,
2006). A conditional knockout of the Ezh2 gene in basal keratino-
cytes leads a precocious acquisition of an epidermal barrier
function in the embryo (Ezhkova et al., 2009), while a conditional
knockout of Ezh2 in B-lymphocytes results in improper IgH
rearrangements (Su et al., 2003), suggesting a role for Ezh2
methyltransferase in cell differentiation and maturation. Ezh2 is
found to be highly expressed in a variety of cancer types where
the genomic loss of miR-101 leads to increased expression of
Ezh2 and concomitant deregulation of epigenetic pathways,
altogether resulting in cancer progression (Varambally et al.,
2008). Furthermore, Ezh2 can induce EMT and increase the
metastatic potential of prostate cancer cells by downregulation
of DAB2IP, a tumor-suppressive Ras GTPase-activating protein
(RasGAP) (Chen et al., 2005; Min et al., 2010). Finally, low Ezh2
expression levels correlate with metastasis-free survival in
breast cancer (Cao et al., 2008; Kleer et al., 2003). However,
whether and how Ezh2-mediated epigenetic mechanisms
contribute to the transcriptional reprogramming that accom-
panies EMT is still poorly understood.
RESULTS
Sox4 Is Required for EMT
To identify critical genes underlying early, intermediate, and late
stages of EMT, we induced EMT in the untransformed normal
murine mammary gland (NMuMG) cell line by treatment with
TGF-b for 0, 1, 4, 7, 10, and 20 days (data not shown). During
this time course, the cells underwent progressive EMT and
acquired a complete mesenchymal morphology (Lehembre
et al., 2008). Motif activity response analysis (MARA) (Suzuki
et al., 2009) of gene expression data derived from the EMT
time course predicted several transcription factor binding motifsto be important regulators of the EMT expression dynamics,
including a motif bound by Sox transcription factors (Figure S1A
available online). Gene expression profiling and quantitative RT-
PCR experiments revealed that Sox4 and Sox9 were the only
Sox family members significantly upregulated in their expression
during TGF-b-induced EMT in NMuMG cells (Figures S1B–S1D).
Sox4 expression was also robustly induced during EMT in a
number of other cellular EMT systems, including TGF-b-induced
EMT in Py2T murine breast cancer cells derived from a tumor
of MMTV-PyMT transgenic mice (Waldmeier et al., 2012), in
MCF10A human breast epithelial cells, in EpRas murine mam-
mary epithelial cells (Figures S1D–S1G), and in humanmammary
epithelial cells (Kloeker et al., 2004). Sox4 expression was also
increased in MCF7 human breast cancer cells that exert full
EMT upon shRNA-mediated knockdown of E-cadherin expres-
sion (Lehembre et al., 2008; Figure S1H).
To directly assess the role of Sox4 and Sox9 in EMT, NMuMG
cells were transfected with a pool of two different siRNAs against
Sox4 (siSox4) and Sox9 (siSox9), as well as siSox4 and siSox9
together, to transiently ablate the expression of Sox4 and Sox9
in the absence and presence of TGF-b, resulting in an efficient
repression of Sox4 and Sox9 expression (Figures 1A; Figures
S1I and S1J). As reported recently (Zhang et al., 2012), Sox4-
ablated NMuMG cells were not able to undergo EMT and
largely retained their epithelial morphology during TGF-b treat-
ment, whereas cells transfected with control-siRNA (siControl)
changed to amesenchymal, fibroblastoid phenotype (Figure 1B).
In contrast, the single ablation of Sox9 did not have any effect on
TGF-b-induced EMT, while the concomitant ablation of Sox4
and Sox9 mimicked the single ablation of Sox4 (Figures S1K
and S1L). Immunofluorescence staining revealed that Sox4
depletion in the absence of TGF-b did not substantially affect
the epithelial morphology of NMuMG cells (Figure 1C). In the
presence of TGF-b, Sox4-depleted cells maintained the epithe-
lial markers E-cadherin and ZO-1 at the cell membrane, and
the expression of the mesenchymal marker N-cadherin was
decreased compared to that observed for TGF-b-treated
siControl cells (Figure 1C). Moreover, TGF-b-mediated remodel-
ing of the cytoskeleton from cortical actin to stress fibers, as
determined by phalloidin staining, and focal adhesion formation,
as determined by paxillin staining, were significantly reduced in
siSox4 cells (Figure 1C; Figure S1M). The failure to lose epithelial
and gain mesenchymal marker expression in TGF-b-treated,
Sox4-depleted cells was further confirmed by immunoblotting
analysis (Figure 1D). Notably, Sox4 depletion in NMuMG cells
treated previously with TGF-b for 15 days caused these mesen-
chymal cells to revert to an epithelial phenotype (Figure 1E).
Similar to NMuMG cells, shRNA-mediated stable knockdown
of Sox4 in Py2T cells markedly delayed TGF-b-induced EMT
(Figures S1N–S1P). Together, these results demonstrate that
Sox4, but not Sox9, is required for the induction and mainte-
nance of TGF-b-induced EMT in murine mammary epithelial
cells.
Sox4 Is Required and Sufficient for Cell Survival and Cell
Migration
Sox4 has been implicated in cell survival in a variety of cancers
(Hur et al., 2010; Pramoonjago et al., 2006; Shen et al., 2010).
Indeed, Sox4-depleted NMuMG and Py2T cells also showed aCancer Cell 23, 768–783, June 10, 2013 ª2013 Elsevier Inc. 769
Figure 1. Sox4 Is Required for EMT
(A) Sox4 mRNA levels were determined by quantitative RT-PCR in NMuMG cells transfected with either control siRNA (siControl) or with siRNA against
Sox4 (siSox4) in the absence or presence of TGF-b for 2 days. Fold changes are relative to those of cells transfected with control siRNA in the absence
of TGF-b.
(B) NMuMG cells transfected with either siControl or siSox4 were treated with TGF-b for the number of days indicated, and their morphology was evaluated by
phase-contrast microscopy. Scale bar, 100 mm.
(C) Immunoflorescence microscopy analysis of changes in the localization and expression levels of marker proteins during EMT. NMuMG cells transfected with
either siControl or siSox4 were left untreated or treated with TGF-b for 2 days and were stained with antibodies against the epithelial markers E-cadherin and
ZO-1, against the mesenchymal marker N-cadherin, against paxillin to detect focal adhesion plaques, and with phalloidin to visualize the actin cytoskeleton.
Scale bar, 50 mm.
(legend continued on next page)
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Figure 2. Sox4 Is Required for Cell Sur-
vival and Cell Migration during TGF-
b-Induced EMT
(A and B) siRNA or shRNA-mediated ablation of
Sox4 expression (siSox4 and shSox4, respectively)
during TGF-b treatment of NMuMG (A) and Py2T (B)
cells results in a significant decrease in cell numbers
compared to transfection with control siRNA or
shRNA (siControl and shControl, respectively).
(C and D) NMuMG cells (C) or Py2T cells (D) trans-
fected with either siControl and shControl or siSox4
and shSox4 were treated with TGF-b for the days
indicated (d0 to d4). Cells were stained with propi-
dium iodide (PI), and the percentages of cells in
G0/G1 and S-G2/M phases of the cell cycle were
determined by flow cytometry.
(E) NMuMG cells transfected with either siControl or
siSox4 were treated with TGF-b for the days indi-
cated, and the rates of apoptosis were determined
by Annexin-V staining and flow cytometry.
(F) shSox4-expressing and shControl-expressing
Py2T murine breast cancer cells were treated for
15 days with TGF-b, and cell migration was deter-
mined in a modified Boyden chamber migration
assay 20 hr after seeding and using 20% FBS as a
chemoattractant.
Statistical values were calculated using an unpaired,
two-tailed t test. *p% 0.05; **p% 0.01; ***p% 0.001.
Error bars indicate the mean ± SD.
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and displayed a discernable sensitivity toward TGF-b-mediated
growth inhibition (Figures 2A and 2B). Propidium iodide staining
followed by flow-cytometry-based cell cycle analysis revealed a
G0/G1 cell cycle arrest after Sox4 depletion (Figures 2C and 2D).
Annexin-V staining demonstrated amarked increase in the levels
of apoptosis in siSox4-transfected NMuMG cells (Figure 2E), but(D) Expression of E-cadherin, N-cadherin, and fibronectin was determined by immunoblotting during TGF-b
siSox4 or siControl. Immunoblotting for actin was used as a loading control.
(E) Morphology of long-term TGF-b-treated NMuMG (NMuMG-LT) cells transfected with either siControl or
Scale bar, 100 mm.
Statistical values were calculated using a paired, two-tailed t test. **p% 0.01; ***p% 0.001. Error bars ind
See also Figure S1.
Cancer Cell 23, 768not in Py2T cells (data not shown). These
results indicate that Sox4 is required for
cell survival and proliferation during TGF-
b-induced EMT and that the prosurvival
function of Sox4 only becomes critical in
nontransformed cells. Cell migration is a
characteristic feature of EMT and metas-
tasis (Brabletz et al., 2005; Christofori,
2006; Gru¨nert et al., 2003; Huber et al.,
2005; Thiery and Sleeman, 2006). Trans-
well migration assays with the apoptosis-
resistant Py2T breast cancer cells revealed
that shSox4 Py2T cells migrated signifi-
cantly less than shControl cells after long-
term treatment with TGF-b (Figure 2F).
We next asked whether Sox4 was suffi-
cient to induce EMT. Transient expressionof HA-tagged Sox4 in NMuMGcells at the levels observed during
TGF-b-induced EMT increased filopodia formation and cell
scattering (Figure 3A) accompanied by the gain of the mesen-
chymal markers N-cadherin and fibronectin (Figures 3B
and 3C). Although its mRNA and protein levels were not appar-
ently affected, E-cadherin was displaced at the cell junctions
of HA-Sox4-expressing cells (Figure 3D). Stable expression of-induced EMT in NMuMGcells transfected with either
siSox4, as evaluated by phase-contrast microscopy.
icate the mean ± SD.
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Figure 3. Ectopic Expression of Sox4 Promotes EMT and Cell Migration
(A) NMuMG cells were transiently transfected with pcDNA3-HA and pcDNA3-HA-Sox4 constructs, and cellular morphology was evaluated. Note the formation of
filopodia and the cell dispersal upon Sox4 expression (HA-Sox4) as compared to empty vector control (Empty). Scale bar, 100 mm.
(B) The expression of E-cadherin (Ecad), N-cadherin (Ncad), fibronectin (Fn1), Ezh2, and Sox4 was determined by quantitative RT-PCR in NMuMG cells
transiently transfected with HA-Sox4 or with empty vector (Empty) in the absence of TGF-b. Fold changes are relative to those in cells transfected with empty
vector.
(legend continued on next page)
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morphology in the absence of TGF-b, with a moderate loss of
E-cadherin expression but a marked gain in N-cadherin and
fibronectin expression (Figures 3E–3G). Furthermore, the forced
expression of Sox4 promoted Py2T cell migration (Figure 3H).
These results suggest that Sox4 is not only required but also suf-
ficient for the induction of an EMT.Sox4 Is Required for Tumorigenesis and Metastatic
Spread
The critical role of Sox4 in EMT raised the question of whether
Sox4 contributes to malignant tumor progression and metas-
tasis. First, computational analysis revealed a significant correla-
tion between high Sox4 expression and poor metastasis-free
survival in the ‘‘Schmidt’’ database of 200 early-stage, lymph-
node-negative breast cancer patients (Schmidt et al., 2008) (Fig-
ure 4A). The analysis of databases assembled of late-stage
breast cancer patient data did not reveal a significant prognostic
value for Sox4 expression (data not shown), suggesting that
Sox4 may play a critical role in the early stages of the malignant
progression of breast cancer.
Next,we investigated the functional contribution of Sox4 topri-
mary tumor growth and metastasis formation in vivo. Py2T cells
stably expressing an shRNA against Sox4 (shSox4) and con-
trol-transfected cells (shControl), both expressing the firefly lucif-
erase gene, were orthotopically implanted into mammary fat
pads of nude mice, and tumor growth and metastasis in lymph
nodes, lungs, and livers were quantified. Quantitative RT-PCR
(Figure S2A) and immunostaining of histological tumor sections
(Figure 4B) documentedanefficient depletionof Sox4expression
in the cultured cell line before implantation and in primary tumors,
respectively. Ablation of Sox4 expression in Py2T cells lead to a
significant reduction in primary tumor growth (Figure 4C). Lucif-
erase activity levels representing the presence of tumor cells in
distant organswere found to bedecreased in axillary and inguinal
lymph nodes and in lungs and livers of mice transplanted with
shSox4 Py2T cells as compared to shControl Py2T cells (Fig-
ure S2B), even when the luciferase activities were normalized to
the decreased primary tumor sizes observed with shSox4 Py2T
cells (metastatic index; Figure 4D). The reduced ability of shSox4
Py2T cells to grow as primary tumors was also observed upon
subcutaneous implantation into nude mice (Figure 4E).
We next addressed whether Sox4 is required for metastasis
formation in other cancer types. Similar to NMuMG cells, in
B16-F10 melanoma cells Sox4 expression was increased upon(C) The expression of E-cadherin, N-cadherin, fibronectin, Ezh2, andHA-tagged S
with empty vector or with HA-Sox4. Actin was used as the loading control.
(D) The localization of E-cadherin was determined by immunofluorescence st
HA-Sox4. The cells marked with an arrow express Sox4 (HA) and have lost E-ca
(E) Cell scattering and mesenchymal morphology are observed even in the absen
compared to empty-vector-transfected control cells (Empty). Scale bar, 100 mm
(F) The expression of E-cadherin (Ecad), N-cadherin (Ncad), fibronectin (Fn1), a
transfected with either HA-Sox4 (Clones 3 and 5) or control vector (Empty) in the ab
control vector.
(G) Immunoblotting analysis of E-cadherin, N-cadherin, fibronectin, Ezh2, and
transfected with HA-Sox4 (Clones 3 and 5) or with empty control vector (Empty)
(H) Cell migration of Py2T cell clones stably transfected with HA-Sox4 (Clones 3
migration assay in the absence of TGF-b after 20 hr of cell seeding with 20% FB
Statistical values were calculated using an unpaired, two-tailed t test. *p% 0.05TGF-b treatment (Figure S2C). Sox4 expression was then abla-
ted in B16-F10 melanoma cells by stable expression of shRNA
targeting Sox4 (shSox4; Figure S2D), and the cells were injected
into the tail vein of C57Bl/6 mice. Quantification of lung
metastasis showed that Sox4-depleted B16-F10 cells were
significantly impaired in lung colonization as compared to
shControl-expressing B16-F10 cells (Figures S2E and S2F).
Taken together, these results indicate that the transcription fac-
tor Sox4 exerts a critical function in primary tumor growth and
metastasis formation.Ezh2 Is a Direct Transcriptional Target of Sox4
The critical role of Sox4 in EMT and tumor progressionmotivated
us to identify the genes that were directly regulated by Sox4. We
first compared the genome-wide gene expression profiles of
siControl and siSox4 NMuMG cells in the absence and presence
of TGF-b. Genes found to be differentially expressed in depen-
dence on Sox4 function were further analyzed for Sox4 binding
motifs within one kilobase of their transcription start sites (Fig-
ure S1A). Of the 189 genes fulfilling these criteria (Table S1),
106 also changed in their expression levels during TGF-
b-induced EMT. Gene ontology analysis revealed that 32 of
these genes have been previously implicated in processes rele-
vant to tumor progression (Table S2). In order to identify the
genes directly regulated by Sox4, we assessed the occupancy
of Sox4 at the promoters of these 32 genes. NMuMG cells tran-
siently expressing an HA-tagged version of Sox4 (HA-Sox4)
were subjected to chromatin immunoprecipitation (ChIP) with
HA-specific antibodies followed by quantitative PCR using
primers specific for the region spanning the Sox4 motif found
in the promoter of these genes. Of the 32 genes analyzed, the
promoters of 28 genes—16 in NMuMG cells and 12 in Py2T
cells—were directly bound by Sox4, including the key EMT
genes Spred1, Edn1, Palld, Cyr61, Ereg, and Areg (Figures
S3A–S3H; data not shown). Genes that were not immunoprecip-
itated by HA-antibody, as well as an intergenic region, served as
negative controls (Figure S3I).
Snail, Zeb, and Twist family transcriptional repressors of
E-cadherin gene expression are known to play critical roles in
the induction of EMT. Hence, we assessed whether Sox4 is
epistatic to the expression of these EMT inducers or whether
they are regulating Sox4 expression during EMT. Ablation of
Sox4 expression in NMuMGcells resulted in the reduced expres-
sion of Snail2, Zeb2, and Twist1, but not Snail1 and Zeb1,
whereas in Py2T cells the expression of all five repressors wasox4was determined by immunoblotting of NMuMGcells transiently transfected
aining in NMuMG cells transiently transfected with empty-vector control or
dherin at their cell membranes. Scale bar, 50 mm.
ce of TGF-b in Py2T cell clones stably expressing HA-Sox4 (Clones 3 and 5), as
.
nd Sox4 was determined by quantitative RT-PCR in Py2T cell clones stably
sence of TGF-b. Fold changes are relative to those of cells transfected with the
HA-Sox4 (HA) during TGF-b-induced EMT in Py2T cell clones either stably
in the absence of TGF-b. Vinculin was used as loading control.
and 5) or transfected with control vector (Empty) was analyzed in a transwell
S as a chemoattractant.
; **p% 0.01; ***p% 0.001. Error bars indicate the mean ± SD.
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Figure 4. Sox4 Is Critical for Breast Carcino-
genesis and Metastasis
(A) Correlation of the levels of Sox4 expression and
prognosis in the ‘‘Schmidt’’ array data set of
lymph-node-negative breast cancers (Schmidt
et al., 2008). Shown is a Kaplan-Meier plot with
survival curves for patient samples classified as
having high Sox4 expression and those classified
as having low Sox4 expression to assess metas-
tasis-free survival.
(B) shSox4-expressing and shControl-expressing
Py2T murine breast cancer cells were injected into
the mammary fat pads of nude mice, and the
resulting tumors were analyzed by immunohisto-
chemistry for Sox4 expression. High magnifica-
tion, as indicated by boxed areas, shows that
shControl-transfected cells localize Sox4 primarily
in the nucleus and exhibit spindle-like cell
morphology, whereas shSox4-expressing cells
lack significant Sox4 expression and exhibit a
more differentiated morphology.
(C) shSox4-expressing and shControl-expressing
Py2T cells were injected into the mammary fat
pads of nude mice, and tumor growth in individual
mice was measured over time (top). Tumor weight
(bottom) was assessed after sacrificing the tumor-
bearing mice 23 days after injection.
(D) Metastatic spread of firefly luciferase-
expressing Py2T cells from the primary tumors
analyzed in (C) was determined by measuring
luciferase activity in extracts of lymph nodes (LN),
lungs, and livers of transplanted mice. Luciferase
activity levels in the various organs were divided by
the primary tumor weights within the same mice to
establish the metastatic index. Numbers indicate
the fold differences between Sox4-expressing
(shControl) and Sox4-depleted (shSox4) Py2T
cells. Error bars indicate the mean ± SE.
(E) Primary tumor growth of shControl and shSox4
Py2T cells upon subcutaneous injection into nude
mice (left). Tumor weight was assessed 27 days
after implantation (right).
Statistical values were calculated using an
unpaired, two-tailed t test. *p% 0.05; **p% 0.01;
***p% 0.001. Error bars indicate the mean ± SEM.
See also Figure S2.
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Conversely, when the five repressors were transiently expressed
in NMuMG and Py2T cells, the levels of Sox4 mRNA were not
affected (Figures S3O and S3U). Together, the data indicate
that Sox4 acts upstream of the EMT inducers during EMT,
most likely in an indirect manner, since none of the EMT inducers
have been detected as a direct transcriptional target of Sox4.
Interestingly, the Sox4-dependent gene expression profiling
and ChIP experiments also revealed the promoter of the Ezh2
gene to be directly bound and regulated by Sox4 in NMuMG
and Py2T cells (Figures 5A and 5B). Quantitative RT-PCR and
immunoblotting showed that Sox4 depletion led to significantly
reduced Ezh2 expression and a global reduction in H3K27me3
levels in the presence of TGF-b in NMuMG and Py2T cells (Fig-
ure 5C). Moreover, the forced expression of Sox4 moderately
increased Ezh2 mRNA and protein levels (Figures 3B, 3C, and
3G). Finally, Ezh2 promoter activity was reduced upon Sox4
depletion in NMuMG cells in the presence of TGF-b, as deter-774 Cancer Cell 23, 768–783, June 10, 2013 ª2013 Elsevier Inc.mined by Ezh2 promoter luciferase reporter assay (Figure 5D).
These results indicate that Sox4 is required for Ezh2 expression
during EMT. However, it should be noted that Ezh2 expression
levels were already substantial in epithelial cells, where Sox4
expression was low and did not markedly change with the
increasing levels of Sox4 during TGF-b-induced EMT (Figures
5E, 5F, and 6B). Hence, Sox4 is required for the efficient expres-
sion of Ezh2 during TGF-b-induced EMT, but not in epithelial
cells in the absence of TGF-b, suggesting that factors other
than Sox4 are critical for Ezh2 gene expression in the epithelial
state of the cells. Consistent with this notion, the dependence
of Ezh2 expression on Sox4 became already apparent between
2 and 8 hr of TGF-b stimulation in NMuMG and Py2T cells (Fig-
ures 5E and 5F).
Loss of Ezh2 Function Impairs EMT and Metastasis
Based on the pleiotropic functions of Ezh2 in mediating the
H3K27me3 repressive mark, we speculated whether a major
Figure 5. Sox4 Directly Regulates Ezh2
Gene Expression
(A and B) NMuMG cells (A) and Py2T cells (B) were
transiently transfected with a construct encoding
HA-Sox4 or empty vector and used for ChIP in the
absence and presence of TGF-b for 2 days using
HA-specific antibodies. Precipitated DNA frag-
ments corresponding toEzh2promoter sequences
were detected by quantitative PCR to assess Sox4
occupancy at this region. Fold changes are relative
to those observed for a PCR reaction with primers
specific for an intergenic region.
(C) Levels of Ezh2 mRNA were determined by
quantitative RT-PCR in NMuMG cells or Py2T
cells transfected with control siRNA (siControl) or
siRNA against Sox4 (siSox4) in the presence of
TGF-b for 2 days. Fold changes are relative to
those in siControl-transfected cells (top). Global
H3K27me3 levels were determined by immuno-
blotting in NMuMG cells or Py2T cells transfected
with siControl or siSox4 and treated with TGF-b
for 2 days. Total histone H3 was used as a loading
control (bottom).
(D) Sox4 regulates Ezh2 promoter activity.
NMuMG cells were transiently transfected with
siControl or siSox4 and with a pGL3 luciferase
reporter plasmid containing a 1.9 kb fragment of
the Ezh2 promoter controlling the expression of
firefly luciferase and then treated with or without
TGF-b for 2 days. Firefly luciferase activity was
normalized to cotransfected renilla luciferase
activity (relative luminescence).
(E and F) Sox4 and Ezh2 expression levels were
determined by quantitative RT-PCR after transient
transfection of NMuMG (E) and Py2T cells (F) with
siControl or siSox4 during the first hours of TGF-b
treatment (0, 2, 4, and 8 hr).
Statistical values were calculated using a paired,
two-tailed t test. *p % 0.05; **p % 0.01; ***p %
0.001. Error bars indicate the mean ± SD.
See also Figure S3 and Tables S1 and S2.
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tion of Ezh2 gene expression. Indeed, similar to the ablation of
Sox4, siRNA-mediated knockdown of Ezh2 (siEzh2) in NMuMG
cells led to an efficient downregulation of Ezh2 and retention of
the epithelial phenotype of NMuMGcells upon TGF-b stimulation
(Figure 6A; Figure S4A). Immunoblotting and immunofluores-
cence microscopy analysis demonstrated a failure to lose
E-cadherin and ZO-1 expression as well as a reduced gain in
the expression of fibronectin and impaired formation of actin
stress fibers and focal adhesions in Ezh2-depleted cells
compared to siControl-treated cells (Figures 6B and 6C). These
effects became even more apparent in NMuMG cells when
both methyltransferases, Ezh1 and Ezh2, were concomitantly
depleted (Figures 6A and 6C; Figures S4B–S4F). Similar to
NMuMG cells, shRNA-mediated stable codepletion of Ezh1
and Ezh2 in Py2T cells also delayed EMT (Figures S4G–S4I).
Comparable to the ablation of Sox4 expression, Ezh2-depleted
NMuMG cells showed significantly increased apoptosis, a block
in G0/G1, and a substantial attenuation in their proliferation dur-
ing TGF-b-induced EMT (Figures 6D–6F). Finally, similar to the
depletion of Sox4 in B16-F10 melanoma cells, shRNA-mediated
ablation of Ezh2 or Ezh1/2 together resulted in a significantlyreduced ability of these cells to form lung metastasis upon intra-
venous injection (Figure S4J). Notably, the concomitant high
expression of Ezh2 and Sox4 significantly correlated with poor
metastasis-free survival of early-stage, lymph-node-negative
breast cancer patients (Schmidt et al., 2008; Figure 6G).
To directly assess whether Ezh2 is the major transcriptional
target of Sox4 required for its EMT-inducing function, we tran-
siently ablated Sox4 in NMuMG and Py2T cells and concomi-
tantly expressed Ezh2 by transient transfection of an Ezh2
expression plasmid. Notably, the forced expression of Ezh2
overcame the reduced expression of endogenous Ezh2 upon
Sox4 depletion and restored TGF-b-induced EMT and changes
in marker expression that otherwise were repressed by Sox4
ablation in NMuMG and in Py2T cells (Figures 7A–7C; Figures
S5A and S5B). These results indicate that Ezh2 is one critical
target of Sox4 transcriptional regulation during EMT and metas-
tasis formation.
Ezh2 Regulates EMT Genes via H3K27me3 Modification
of Their Promoters
To identify the target genes that are modified by Ezh2-mediated
H3K27me3 epigenetic imprint and regulated in their expressionCancer Cell 23, 768–783, June 10, 2013 ª2013 Elsevier Inc. 775
Figure 6. Depletion of Ezh2 Phenocopies the Ablation of Sox4 during TGF-b-Induced EMT
(A) NMuMG cells transfected with either control siRNA (siControl) or with siRNAs against Ezh2 or Ezh1 and Ezh2 together (siEzh1/2) were treated with TGF-b for
the days indicated, and their morphology was evaluated by phase-contrast microscopy. Scale bar, 100 mm.
(B) Expression of E-cadherin, N-cadherin, ZO-1, and Ezh2 was determined by immunoblotting analysis during TGF-b-induced EMT in NMuMG cells transfected
either with siEzh2 or siControl. Immunoblotting for actin was used as a loading control.
(legend continued on next page)
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Figure 7. Forced Expression of Ezh2 Overcomes the Lack of Sox4 and Restores TGF-b-Induced EMT
(A) Although ablation of Sox4 expression (siSox4) repressed the TGF-b-induced mesenchymal morphology of NMuMG cells observed in siControl-transfected
cells, transient expression of Ezh2 in Sox4-ablated cells (siSox4 + Ezh2) restored EMT and mesenchymal cell morphology. Cells were treated with TGF-b for the
indicated times. Scale bar, 100 mm.
(B and C) mRNA expression levels of E-cadherin (C) and fibronectin (D) were determined after Ezh2 overexpression (+Ezh2) in control (shControl) and Sox4-
ablated (shSox4) Py2T cells.
Statistical values were calculated using an unpaired, two-tailed t test. *p% 0.05; **p% 0.01; ***p% 0.001.
See also Figure S5.
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using an H3K27me3-specific antibody upon TGF-b treatment
in NMuMG cells for 0, 1, 4, 7, 10, and 20 days followed by
next-generation sequencing (ChIP-Seq) in combination with
gene expression profiling. Whole-genome scanning revealed
970 regions corresponding to 301 genes with high variance in
H3K27me3 levels during EMT and high reproducibility in the
biological replicates (Figure 8A). Among the 301 genes,(C) Immunoflorescencemicroscopy analysis of NMuMG cells transfected with eith
and stained with antibodies against E-cadherin, ZO-1, and fibronectin, and with
(D) NMuMG cells transfected with either siControl or siEzh2 were treated with T
Annexin-V staining and flow cytometry.
(E) siControl- and siEzh2-transfected NMuMG cells were treated with TGF-b fo
percentages of cells in G0/G1 and S-G2/M phases of the cell cycle were determ
(F) siRNA-mediated ablation of Ezh2 expression during TGF-b treatment of NMu
fection with control siRNA.
(G) Kaplan-Meier survival curve for patient samples of the ‘‘Schmidt’’ data set of l
concomitant low Sox4 and Ezh2 expression and high Sox4 and Ezh2 expression
Statistical values were calculated using an unpaired, two-tailed t test. *p% 0.05
See also Figure S4.genome-wide gene expression analysis identified 46 genes
that were transcriptionally upregulated during EMT and lost their
H3K27me3 marks and three genes that were transcriptionally
downregulated during EMT and gained H3K27me3 marks (Fig-
ure S6A). We validated the changes in H3K27me3 levels at target
gene promoters such as Mcam, Pdgfrb, Itga5, Col4a1, and
St6galnac4 in NMuMG and Py2T cells (Figures 8B and 8C; Fig-
ure S6B) by ChIP followed by quantitative PCR for the promoterer siControl or with siEzh2 or siEzh1/2. Cells were treated with TGF-b for 7 days
phalloidin to visualize the actin cytoskeleton. Scale bar, 50 mm.
GF-b for the days indicated, and the rates of apoptosis were determined by
r the days indicated. Cells were stained with propidium iodide (PI), and the
ined by flow cytometry.
MG cells results in a significant decrease in cell numbers compared to trans-
ymph-node-negative breast cancers (Schmidt et al., 2008) classified as having
, to assess metastasis-free survival.
; **p% 0.01; ***p% 0.001. Error bars indicate the mean ± SD.
Cancer Cell 23, 768–783, June 10, 2013 ª2013 Elsevier Inc. 777
Figure 8. TGF-b-Induced EMT Accompanies Genome-wide Reprogramming of the Polycomb-Associated Mark H3K27me3
(A) TGF-b-induced EMT accompanies genome-wide reprogramming of the Polycomb-associated mark H3K27me3. Genome-wide H3K27me3 enrichment
above background was calculated for 2-kb-wide windows overlapping by 1 kb. To extract those H3K27me3-regions that are most relevant for EMT dynamics, for
each region both the variance in H3K27me3 levels during the progressive stages of EMT (horizontal axis) and the reproducibility of the H3K27me3 dynamics
across biological replicates (vertical axis) were calculated, and 970 genes with high variance and high reproducibility were selected. Comparison of these regions
with RefSeq transcripts show that they fall within 1 kb upstream and downstream of 301 distinct target genes.
(legend continued on next page)
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appeared highly dependent on the presence of Ezh1/2 and the
H3K27me3 repressive imprint. For example, the promoters of
the Mcam, Pdgfrb, and Itag5 genes were found to be highly en-
riched in H3K27me3marks in untreated NMuMG cells. Depletion
of Ezh1/2 led to a loss of global H3K27me3 levels (Figure S6C)
and of H3K27me3 at the promoters of the Mcam, Pdgfrb, and
Itag5 genes (Figure 8D; Figure S6D), with a concomitant increase
in the expression of these genes (Figures 8E and 8F; Figures S6E
and S6F) in NMuMG and Py2T cells. Conversely, the Sgsh gene
gained H3K27me3 at its promoter during TGF-b-induced EMT,
with a concomitant repression of its expression, and upon
Ezh1/2 depletion, the lack of H3K27me3 marks on the Sgsh pro-
moter during TGF-b-treatment resulted in increased Sgsh gene
expression (Figure 8G). In addition, we validated a subset of
other H3K27me3-enriched genes that changed in their expres-
sion profile upon depletion of Ezh1/2 (Figure 8H). Gene ontology
analysis revealed a prominent enrichment for gene functions
implicated in EMT, malignant tumor progression, andmetastasis
(Figure S6G). Furthermore, analysis of the ‘‘Minn’’ database of
breast cancer (Minn et al., 2005) revealed that the 49 genes
signature correlated with reduced bone-metastasis-free survival
of patients in highly malignant breast cancers lacking estrogen
receptor expression (ER) or lacking estrogen receptor, proges-
terone receptor, and ErbB2 expression (triple-negative [TN];
Figures S6H–S6K). Moreover, in the ‘‘Schmidt’’ database of
early-stage breast cancer (Schmidt et al., 2008), the 49 genes
signature correlated with the probability to develop distant
metastasis (Figure S6L). In line with these findings, transwell
migration assays revealed significantly lower chemotactic
migration of NMuMG and Py2T cells depleted of both Ezh1
and Ezh2 (Ezh1/2) as compared to siControl-transfected cells
upon treatment with TGF-b (Figure S6M). Together, these data
indicate that Sox4 regulates Ezh2 gene expression, that Ezh2-
mediated H3K27me3 marks are critically involved in the tran-
scriptomic reprogramming of cells undergoing EMT, and that
an epigenetic EMT gene signature correlates with survival in
breast cancer patients.
DISCUSSION
EMT is accompanied by massive changes in cell morphology
and behavior, and transcription factors play a pivotal role in con-
trolling the various cellular functions during EMT, such as cell
proliferation, cell survival, cell differentiation, cell migration,(B and C) ChIP was performed using an H3K27me3-specific antibody in NMuMG
the promoters of the Mcam, Pdgfrb, and Sgsh genes during TGF-b-induced EM
absence of TGF-b (C). Average enrichments from independent assays are plotted
further normalized to the Gapdh housekeeping gene promoter.
(D) ChIP was performed using an H3K27me3-specific antibody in NMuMG cells
(siEzh1/2), and quantitative PCR was performed using promoter-specific primers
Itga5 promoters and normalized to the Gapdh housekeeping gene promoter.
(E–G) NMuMG cells transiently transfected with control siRNA (siControl) or siRN
themRNA expression levels ofMcam (E) andPdgfrb (F), which already carry high H
of Sgsh (G), which gains this mark upon TGF-b treatment for 1, 4, 7, and 10 day
(H) Validation of selected genes enriched in H3K27me3 marks and their transc
of TGF-b.
Statistical values were calculated using a paired, two-tailed t test. *p% 0.05; **p
See also Figure S6 and Tables S1 and S2.and cell adhesion. (Hanahan and Weinberg, 2011; Kalluri,
2009; Kalluri and Weinberg, 2009; Nieto, 2010; Polyak and
Weinberg, 2009; Thiery and Sleeman, 2006). In this study, the
transcription factor Sox4 was found to be upregulated in its
expression and transcriptional activity during EMT in a number
of murine and human nontransformed mammary gland epithelial
cells and breast cancer cells. The upregulated expression of
Sox4 during TGF-b-induced EMT in NMuMG cells was indepen-
dent of canonical TGF-b signaling, since shRNA-mediated abla-
tion of Smad4 did not substantially affect Sox4 expression (data
not shown). Moreover, treatment of NMuMG and Py2T cells with
inhibitors against various signaling pathways revealed that the
inhibition of TGF-b receptor and Notch signaling and the activa-
tion of Wnt signaling interfered with TGF-b-induced Sox4
expression, whereas the inhibition of EGF receptor increased
Sox4 mRNA levels (data not shown). These observations sug-
gest a complex gene regulatory network that drives the
increased expression of Sox4 during the early phases of TGF-
b-induced EMT, perspectives that warrant further investigation.
We show that Sox4 is required not only for the initiation of EMT
but also for its maintenance. Furthermore, Sox4 is crucial for pri-
mary tumor growth andmetastatic spread of Py2T breast cancer
and B16-F10 melanoma cells. Finally, we find a significant pos-
itive correlation between increased Sox4 expression and the
metastatic potential of early-stage, lymph-node-negative breast
cancer in patients. These results are consistent with a recent
report demonstrating that Sox4 is critical for EMT and tumor
growth of human breast cancer cells and that Sox4 correlates
with poor prognosis in cancer patients (Zhang et al., 2012).
Despite the recent implications of Sox4 in EMT, its direct tran-
scriptional target genes have remained elusive. Here, we show
that Sox4 exerts its central function in EMT and tumor progres-
sion by directly regulating the expression of a number of genes
implicated in EMT, cell cycle regulation, cell survival, and cell
migration. Notably, one of the direct targets of Sox4 transcrip-
tional control is Ezh2, and ablation of Ezh2 function phenocopies
the loss of Sox4 during TGF-b-induced EMT. Moreover, the
forced expression of Ezh2 overcomes the failure of Sox4-defi-
cient cells to undergo EMT. These results indicate that Ezh2 is
a critical downstream effector of Sox4 and that Sox4 mediates
epigenetic reprogramming by regulating the expression of epige-
netic modulators during EMT. Consistent with this notion, the
concomitant high expression of Sox4 and Ezh2 correlates with
poor prognosis in a subset of breast cancer patients. These find-
ingsare indeedhighly relevant, since theyunravel acombinatorialcells and the enrichment of H3K27me3 was determined by quantitative PCR at
T (B) and at the promoters of the Itga5, Col1a1, and St6galnac4 genes in the
on the y axis as the ratio of precipitated DNA relative to the total input DNA and
transiently transfected with control siRNA (siControl) or siRNA against Ezh1/2
as indicated to determine enrichment of H3K27me3 at theMcam, Pdgfrb, and
A against Ezh1/2 (siEzh1/2) were analyzed by quantitative RT-PCR analysis for
3K27me3marks in untreated NMuMGcells and lose thismark during EMT, and
s.
riptional derepression after Ezh1/2 ablation in NMuMG cells in the absence
% 0.01; ***p% 0.001. Error bars indicate the mean ± SD.
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driving the transcriptional reprogramming underlying cell-fate
changes during morphogenic processes such as EMT.
The methyltransferase Ezh2 is the best-studied component of
the Polycomb repressor complex 2 (PRC2). Increased expres-
sion or activity of Ezh2 is a marker of advanced and metastatic
disease in many solid tumors, including prostate and breast
cancer (Chase and Cross, 2011). Our genome-wide study of
Ezh2-associated H3K27me3 marks during EMT revealed
dynamic changes at a number of genes, of which a subset also
show corresponding changes in transcriptional state. We further
show that Ezh1 and Ezh2 together determine global as well as
promoter-specific H3K27me3 levels. This activity modulates
the transcriptional state of target genes, including a number of
EMT-relevant genes, and it is a prerequisite for EMT. Notably,
this epigenetic EMT signature significantly correlates with poor
clinical outcome in patients with highly aggressive and metasta-
tic ER and triple-negative breast cancer. Thus, Polycomb-
mediated transcriptional regulation is a critical contributor to
the maintenance of epithelial differentiation and to transcrip-
tomic reprogramming during EMT.
Previously, single-gene studies have suggested a role for Ezh2
in EMT regulation. For example, the PRC2 complex is recruited
to the promoter of the Cdh1 gene for its repression (Cao et al.,
2008; Rhodes et al., 2003), and Snail1-mediated repression of
Cdh1 during stem cell differentiation is PRC2-dependent (Her-
ranz et al., 2008). Notably, Ezh2 forms a corepressor complex
with HDAC1, HDAC2, and Snail to repress Cdh1 expression
and to promote nasopharyngeal carcinoma malignancy (Tong
et al., 2012). Moreover, the loss of integrin b4 expression during
EMT correlates with a decrease in the activating histone modifi-
cations H3K9Ac and H3K4me3 and an increase in the repressive
histone modification H3K27me3 at its promoter (Yang et al.,
2009). Thus, previous single-gene studies have clearly demon-
strated a role of PcG-mediated mechanisms in carcinogenesis
(Mills, 2010; Sauvageau and Sauvageau, 2010; Sparmann and
van Lohuizen, 2006). By identifying genome-wide targets of the
PcG machinery during the stepwise progression of EMT and
showing a direct role of Ezh1 and Ezh2 in the transcriptional
regulation of key EMT genes, our study establishes awidespread
and crucial role for PcG in EMT. We show that the transcription
factor Sox4 acts upstream of epigenetic reprogramming events
during EMT by directly regulating expression of the chromatin
regulator Ezh2. Once expressed, Ezh2 and its accompanying
chromatin regulators need to be recruited to specific target
genes during EMT. It is surprising that we have not identified
the EMT inducers Snail1/2, Twist1/2, and Zeb1/2 as direct tar-
gets of PcG-mediated regulation or Sox4 transcriptional control.
Yet, given the critical role of Snail1/2, Twist1/2, and Zeb1/2 in
regulating EMT and in associating with chromatin regulators, it
will be important to further delineate the crosstalk of these pro-
teins with the epigenetic machinery and to assess whether and
how they are targeting epigenetic regulators to specific target
genes.
Sox4 has been linked to the etiology of certain cancer types
(Penzo-Me´ndez, 2010). Interestingly, the closely related family
member Sox2 is one of the transcriptional factors required to
reprogram somatic cells into induced pluripotent stem (iPS) cells
(Takahashi and Yamanaka, 2006). In glioma-initiating cells, a780 Cancer Cell 23, 768–783, June 10, 2013 ª2013 Elsevier Inc.crosstalk between Sox4 and Sox2 has been implicated in main-
taining the tumorigenicity of the cells by Sox4 binding to theSox2
gene enhancer region (Ikushima et al., 2009). Together with pre-
vious reports that EMT increases the tumor-initiating (cancer
stem cell) potential of cancer cells (Mani et al., 2008; Morel
et al., 2008), our observation that Sox4 is required for EMT and
for metastasis make Sox4 an exciting target for further investiga-
tion. Our experimental results indicate that Sox4 exerts its critical
regulatory functions upstream of the Snail, Zeb, and Twist family
transcriptional inducers of EMT, but without directly affecting
their expression. The promoters of the known EMT regulators
such as Snail1/2, Zeb1/2, or Twist1/2 also did not show any
changes in H3K27me3 levels during EMT and were not affected
following Ezh1/2 depletion (data not shown), suggesting that
different regulatory pathways may underlie their expression
dynamics during EMT. This suggests that independent regula-
tory pathways converge to control genes that drive EMT. These
findings support our efforts to comprehensively understand the
gene regulatory networks that underlie EMT. A recent report
demonstrated that Sox9 cooperates with Snail2 to determine
mammary stem cells and to promote malignant tumor progres-
sion (Guo et al., 2012), yet our study did not find a requirement
of Sox9 for TGF-b-induced EMT in NMuMG and Py2T cells. In
contrast, another Sox family member, Sox3, was shown to coun-
teract the expression of the EMT-inducer Snail1, and conversely,
Snail1 represses Sox3 gene expression during gastrulation and
in human breast cancer cells (Acloque et al., 2011). We can
only speculate that the differences between these findings may
be based on the functional variety of Sox family members, which
are classified into subgroups by the differences in their protein
moieties outside of the HMG DNA binding domains and their
varying biological functions (Chew and Gallo, 2009).
In summary, the data presented here provide critical insights
into the regulatory networks by which one transcription factor,
Sox4, regulates an important cell-fate determination event,
namely, EMT. Notably, the observation that Sox4 regulates a
number of EMT-relevant genes and Ezh2, and that Ezh2modifies
the expression of a number of genes known to be critical for
EMT, exemplifies a critical interplay between transcriptional
and epigenetic control during EMT. Our data suggest that the
inhibition of Ezh2 function could be an attractive alternative for
therapeutic intervention during malignant tumor progression.
Indeed, early results with the Ezh2 inhibitor 3-deazaneplanocin
(DZNep) are encouraging (Crea et al., 2011), and first results
from clinical trials are impatiently awaited.
EXPERIMENTAL PROCEDURES
For more details see Supplemental Information.
Cell Lines
A subclone of NMuMG cells (NMuMG/E9, hereafter NMuMG) and MCF7-
shControl and MCF7-shEcad have been described previously (Lehembre
et al., 2008; Maeda et al., 2005). B16-F10 melanoma cells, EpRas, and
MCF10A cells were commercially available. Py2T cells were derived from a
breast tumor of MMTV-PyMT transgenic mice (Waldmeier et al., 2012).
Chromatin Immunoprecipitation
ChIP experiments were performed as previously described (Weber
et al., 2005). In brief, crosslinked chromatin was sonicated to achieve an
average fragment size of 500 bp. Starting with 100 mg of chromatin and 5 mg
Cancer Cell
Sox4 Regulates EMT via Ezh2of anti-HA antibody or anti-H3K27me3 antibody, 1 ml of ChIP material and 1 ml
of input material were used for quantitative real-time PCR using specific
primers covering the motif of Sox4 in the promoter of target genes or covering
the 1000 bp promoter region from the transcription start site. Primers covering
an intergenic region were used as a control. The efficiencies of PCR amplifica-
tion were normalized to the PCR product of the intergenic region. Primer
sequences are listed in the Supplemental Information.
Next-Generation Sequencing Analysis
The reads were mapped to the mouse genome assembly NCBI37/mm9 using
the bowtie algorithm (Langmead et al., 2009), which allows up to two mis-
matches within the 36-bp-long sequence. Reads that mapped to more than
100 loci were discarded from the subsequent analysis. In total, 24–34 million
reads were mapped to the genome in the first replicate and 95–106 million
reads to the genome in the second replicate. The mean DNA fragment size
was estimated from the mapping profile on both chromosome strands, and
the reads were shifted by the half of the size toward themiddle of the fragment.
These data were exported to wiggle tracks for manual inspection in the UCSC
genome browser and served as an input for the enrichment analysis. The
genome was tiled with 2 kb windows overlapping by 1 kb, and each window
was summarized by the numbers of reads in both replicates at every stage
and the number of reads in the input DNA. The H3K27me3-enrichment was
calculated assuming binomial statistics of the read counts,
z=
PS
i = 1
fi
S
 fbﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPS
i = 1
fi 3 ð1 fiÞ
S2Ni
+
fb3 ð1 fbÞ
Nb
s ;
where fi = ni=Ni is the frequency in the 2 kb window calculated from the
number of reads in the window, ni, and the total number of reads, Ni , in
sample i, and S = 12 is the number of samples in both replicates. The back-
ground frequencies, fb, are calculated analogously. Neighboring windows
with zR5 and nb%50 were merged and intersected with RefSeq loci extended
by 1 kb upstream and 1 kb downstream. From the list of 96,224 such enriched
regions a subset was selected by requiring dynamic (mean variance log-
frequencies >0.2) and consistent (Pearson correlation coefficient of log fre-
quencies >0.5) methylation changes. The resulting 970 regions lie within
1 kb of the loci of 301 genes.
Animal Experimentation
All studies involving mice have been approved by the Swiss Federal Veterinary
Office (SFVO) and the regulations of the Cantonal Veterinary Office of Basel
Stadt (licenses 1878, 1907, and 1908).
Statistical Analysis
Statistical analysis and graphs were generated using theGraphPad Prism soft-
ware (GraphPad Software, San Diego, CA). All statistical analysis was done by
unpaired/paired, two-sided t test.
ACCESSION NUMBERS
Gene expression data for Sox4 knockdown cells in the presence and absence
of TGF-b in NMuMG cells and ChIP-seq data of H3K27me3 imprints during
TGF-b-induced EMT in NMuMG cells are deposited in the Gene Expression
Omnibus (GSE44050 and GSE45579, respectively).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, and Supplemental
Experimental Procedures can be found with this article online at http://dx.
doi.org/10.1016/j.ccr.2013.04.020.
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